User Fees Would Recede In Significance Under President’s Budget
This article was originally published in The Tan Sheet
Executive Summary
FDA would gain a 6% increase under administration’s blueprint, which stands no real chance of being implemented but could be overture to industry as user fee negotiations approach.
You may also be interested in...
FDA’s Budget Proposal: It’s The User Fees’ Agency Now
User fees, not appropriations, will make up the bulk of FDA’s human drug spending if President Obama’s FY 2014 budget comes to pass, a trend fueled by new user fee programs and cuts to taxpayer funding.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.